15 followers
The one-month antiretrovirals retention in metabolically active animal predictively leads to 4 months or longer retention in non-human primates or even longer in humans.
The one-month antiretrovirals retention in metabolically active animal predictively leads to 4 months or longer retention in non-human primates or even longer in humans.
RT @ColonicD: A new combination bictegravir+tenofovir alafenamide nanoformulation with prolonged sustained-drug-release potency for HIV-1 P…
A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolong… https://t.co/JjMatelRXi
A new combination bictegravir+tenofovir alafenamide nanoformulation with prolonged sustained-drug-release potency for HIV-1 PrEP: A concept evaluation study https://t.co/GIPoHvbeFj